Article Text
Statistics from Altmetric.com
Neurological diagnosis is based upon the clinical assessment, the history and examination. How can we make an appropriate diagnosis without an adequate clinical assessment? “Fundoscopy—discs not seen”, “ophthalmoscope not available”, or simply a blank space where the ophthalmoscopy findings should appear, are commonly seen in the notes of patients admitted with neurological problems across the world. One recent study found that only 30% of such patients recalled being examined with an ophthalmoscope.1 This unsatisfactory situation must be putting patients at risk. A ‘what if’ game brings out the critical importance of ophthalmoscopy: consider the differential diagnosis and management (and urgency of investigations) if the same patient had bilateral papilloedema, unilateral optic atrophy, etc. Despite its readily demonstrable importance in clinical assessment, ophthalmoscopy risks being dropped—along with many a departmental ophthalmoscope—as a routine part of examination. All doctors own a stethoscope—and most an expensive mobile phone—but only neurologists seem to own an …
Linked Articles
- Review
- Review
- Review
- Neurological dilemmas
- A difficult case
- Test yourself
- Neurological rarities
- Neuromythology
Other content recommended for you
- Brain abscess as an initial presentation in a patient of hereditary haemorrhagic telangiectasia caused by a novel ENG mutation
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Pulmonary arteriovenous fistula complicated by venous thromboembolism and paradoxical cerebral infarction during early pregnancy
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- SMAD4 mutations found in unselected HHT patients
- Recurrent minor strokes/TIA with a right to left shunt
- Natalizumab and PML: a risky business?
- Rare manifestations in a case of Osler-Weber-Rendu disease
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients